Clinical Trials
Breaking the Cycle of Excess Mucus, Inflammation, and Infection
ARINA·1 is a novel, at-home nebulized therapy that restores lung health by clearing mucus, reducing inflammation, and inhibiting bacterial growth. ARINA-1 is currently being developed for the prevention of BOS progression in lung transplant for the treatment of non-CF bronchiectasis (NCFBE) and chronic bronchitis (CB).
General Questions About Clinical Trials?
What are clinical trials?
Am I required to participate in clinical trials?
What if I’m interested in participating?
Can I stop being in the clinical trial if I want to?
Is this drug safe to take?
Over 25 patient-years of clinical safety and efficacy data supported
by clean chronic toxicology data.
What are the different phases of a clinical trial?
Phase 1
Safety testing to ensure that therapy has an appropriate safety profile for a population.
Phase 2
Efficacy testing in a small number of patients to gain insight into the efficacy and further assess safety.
Phase 3
Large-scale efficacy testing in the target patient population. Phase 3 trials provide the key data on how well the drug works in a given population and allow a company to submit the data to the FDA and other regulatory agencies around the world for approval for that population of patients.
Target Indications
In our target diseases, thick mucus often accumulates in the lungs and cannot be effectively cleared out of the airways, which leads to mucus plugging and difficulty breathing.
